Click here for flash
Register for Updates
Be notified when new content and features are added to CLLPerspectives.com. Go
CLL Perspectives features the latest news and clinical information about CLL, brought to you in part by our advisory board of leading CLL experts. Access up-to-date clinical reviews, download educational resources and hear from our advisors on key topics in CLL. Our goal is to help you achieve better outcomes for your CLL patients. Learn more about us.
Featured Perspectives

Farrukh Awan, MD, MS
John C. Byrd, MD

Staging and Prognostic Factors in CLL

Thus far, no study has shown a survival advantage with early treatment in patients with CLL and a subset of CLL patients will never require therapy. This has led to the research efforts in CLL that have identified several specific biologic or clinical prognostic factors that predict time to progression and overall survival. With these recent...

Constantine S. Tam, MB, BS Susan Lerner, MS
Michael J. Keating, MB, BS

New Prognostic Markers in CLL

The recent proliferation of new "prognostic markers" in chronic lymphocytic leukemia (CLL) has provided valuable insights into the biology of the disease.1 In particular, significant survival differences when patients are classified by immunoglobulin heavy chain variable region (IGVH) mutation status2,3, fluorescent in-situ hybridization (FISH)...
Read more Read more

News & Commentary - provided by Medworm

 
Impact of the host genetic background on prognosis of chronic lymphocytic leukemia

(Source: Blood)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Source: Blood - Thursday, February 04, 2010

Ofatumumab

Authors: Michael J. Keating, Argyris Dritselis, Uma Yasothan & Peter Kirkpatrick Ofatumumab (Arzerra; Genmab/GlaxoSmithKline) — a fully human cytolytic monoclonal antibody that is specific for CD20 — was approved by the US FDA for the treatment of chronic lymphocytic leukaemia in October 2009. (Source: Nature Reviews Drug Discovery)

Source: Nature Reviews Drug Discovery - Monday, February 01, 2010

Complications of chronic lymphocytic leukemia: Analysis of 203 cases in China

Chronic lymphocytic leukemia (CLL) patients are prone to various complications, such as infections, autoimmune diseases (AID), second tumors or transformations. CLL is the most frequent type of leukemia in the western world, but it is rarely seen in Asian countries . Very limited data published in Chinese patients with respect to the incidence rate, category and prognosis of CLL complications. To explore the characteristics of complications in Chinese CLL patients, 203 cases of CLL patients from the Institute of Hematology and Blood Diseases Hospital, Tianjin, China, from the year 2000 to 2007 were reviewed and followed-up retrospectively. (Source: Leukemia Research)

Source: Leukemia Research - Saturday, January 30, 2010

The TCL1 mouse as a model for chronic lymphocytic leukemia

Abstract: The TCL1 mouse has been proposed as a mouse model for chronic lymphocytic leukemia. This review details how it resembles the aggressive form of the disease rather than the more common indolent form. Although fulfilled predictions in the human disease based on investigations in the mouse model are at present lacking, there are remarkable similarities between human and mouse leukemias that have led to interesting observations on the pathophysiology of chronic lymphocytic leukemia and have identified putative therapeutic targets. (Source: Leukemia Research)

Source: Leukemia Research - Saturday, January 30, 2010

Citrobacter koseri Cellulitis During Anti-CD20 Monoclonal Antibody (Ofatumumab) Treatment for B-cell Chronic Lymphocytic Leukaemia.

Authors: Kluger N, Cartron G, Bessis D, Guillot B, Girard C PMID: 20107742 [PubMed - in process] (Source: Acta Derm Venereol A...)

Source: Acta Derm Venereol A... - Saturday, January 30, 2010